Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 07 symbols : Azn save search
Non-steroidal Anti-inflammatory Drugs Market Research Report by Disease Indication, Drugs, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-07 (Crawled : 16:00) - prnewswire.com
RBGPF | $51.8 8K
|
Consumer Non-Durables
|
| O: 0.06%
H: 3.15%
C: 0.15%
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -6.74%
SNYNF | $92.966 630
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: -4.28%
AZNCF | $135.94 770
|
Health Technology
|
| O: -0.56%
H: 0.61%
C: 0.01%
RBGLY | $10.49 5.1M
|
Manufacturing
|
| O: 0.51%
H: 0.48%
C: -0.14%
VTRS | $11.15 -1.5% 2.3M
|
Health Technology
|
| O: 0.0%
H: 0.55%
C: -0.27%
ZTS | $152.46 1.8% 1.9M
|
Health Technology
|
| O: -0.06%
H: 0.54%
C: -1.77%
PRGO A | $30.15 0.07% 400K
|
Health Technology
|
| O: -0.09%
H: 0.47%
C: -0.28%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.98%
H: 0.24%
C: -1.78%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.21%
H: 1.6%
C: 0.72%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: 0.0%
AZN | $68.38 -0.51% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
covid-19 research global disease report impact distribution market
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
AZN | $68.38 -0.51% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast positive cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
AZN | $68.38 -0.51% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast cancer her2- her2 metastatic breast cancer
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.